The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 8 17a
Copyright © 2005 by The Endocrine Society
Endocrinology & Metabolism News, August 2005
 |
Endocrine Discovery
|
|---|
Treatment of patients with new onset type 1 diabetes with a humanized anti-CD3 antibody maintained residual beta cell function better than placebo for up to 18 months in a randomized controlled trial
(New Engl J Med (June 23, 2005) 352:598)
A NIH panel on "Management of Menopause-Related Symptoms" reported its evidence-based review, concluding that 1) hot flashes, night sweats and vaginal dryness are clearly related to menopause; 2) estrogen is the most consistently effective treatment and this benefit must be balanced against its risks; and 3) the efficacy and safety of alternative therapies require further study.
(Ann Int Med (June 21, 2005) 142:1003)
Higher circulating levels of oxidized LDL and Lp(a) were strongly associated with obstructive coronary artery disease, especially in patients 60 years old or younger—suggesting that Lp(a)’s binding to proinflammatory oxidized phospholipids may be an important contributor to its atherogenicity.
(N Engl J Med (July 7, 2005) 353:46)[Abstract/Free Full Text]
In 50 adult type 1 diabetic patients randomized to insulin therapy insulin with or without rosiglitazone for 8 months, added rosiglitazone improved glycemic control and blood pressure, whereas to achieve comparable glycemic control with insulin alone, an 11% dose increase was required.
(Diabetes Care (July 2005) 28:1562)[Abstract/Free Full Text]
Treatment of 107 adults with insulin-requiring type 2 diabetes with either continuous subcutaneous insulin or multiple daily injections of glargine and lispro insulins resulted in similar degrees of glycemic control, episodes of hypoglycemia, weight gain, and treatment satisfaction over 12 months.
(Diabetes Care (July 2005) 28:1568)[Abstract/Free Full Text]
In previously operated patients with nonfunctioning pituitary adenomas, dopamine agonist therapy for residual tumor growth was associated with more frequent tumor stabilization or shrinkage compared to untreated patients in a retrospective cohort study.
(Clin Endocrinol (July 2005) 63(1):39)
A survey of reproductive health concerns in almost 6,000 Australian men 40 years and older revealed erectile dysfunction in 21%, 30% of whom had sought medical assistance
(Lancet (July 16, 2005) 3666:183)[CrossRef]
During 15,968 patient-years of follow-up after radioiodine treatment of hyperthyroidism, there was an increase in all-cause and circulatory deaths (1.14; 95% CI, 1.04–1.24; and 1.33; 95% CI, 1.14–1.53, respectively) in those who either had not begun or did not require thyroxine therapy, but not those who were already on thyroid hormone replace-ment—suggesting excess cardiovascular mortality from hypothyroidism.
(JAMA (July 6, 2005) 294:71–80)[Abstract/Free Full Text]
|
Endocrine Policy
|
|---|
First-dollar Medicare coverage for ACE inhibitors to slow progression of diabetic renal disease would save lives and money (+0.23 quality-adjusted life-years and $1606 per patient) compared with the new Medicare drug benefit program, based on a cost-effectiveness analysis.
(Ann Int Med (July 19, 2005) 143:89)[Abstract/Free Full Text]
|
Endocrinologists
|
|---|
Charis Eng
will become Director of the Genomic Medicine Institute at Cleveland Clinic Foundation, and Professor and Vice Chairman for the Department of Genetics at Case Western Reserve.
Robert Rizza of the Mayo Clinic is the new President of the American Diabetes Association.
|
Milestones in Endocrinology
|
|---|
75 years ago, Rowntree and Greene successfully treated a patient with Addison’s disease with an adrenal extract prepared by Swingle and Pfiffner.
(JAMA 96:231–235)
|
In the Journal 25 Years Ago
|
|---|
Shapiro G, Evron S. A novel use of spironolactone: treatment of hirsutism.
J Clin Endocrinol Metab 1980;51:429–432.[Abstract]
The encouraging results obtained with spironolactone and the absence of serious side-effects warrant a wider use of the drug in the treatment of excessive hair growth in women.
|
In the Journal 50 Years Ago
|
|---|
Lindsay S, Dailey ME. Malignant lymphoma of the thyroid gland and its relation to Hashimoto disease: a clinical and pathologic study of 8 patients.
J Clin Endocrinol Metab 1955;15:1332–1353.
Eight cases of malignant lymphoma (lymphosarcoma) of the thyroid gland are described. The thyroid glands of 7 of the 8 patients also displayed the lesions of Hashimoto disease. It was concluded from this study that a significant relationship exists between these two processes.
|
Footnotes
|
|---|
Readers are encouraged to suggest items for Endocrinology and Metabolism News by email (sherman{at}endo-society.org). Submissions will be considered based on their significance and timeliness.
Top
Endocrine Discovery
Endocrine Policy
